Clinical Trial Update: GW572016 to Treat Recurrent Malignant Brain Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of GW572016 (lapatinib) for recurrent malignant brain tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme
• Glioma
• Gliosarcoma

Drugs mentioned

• GW572016 (lapatinib) (lapatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Glioma, Brain Tumor | Phase 2 | Status: COMPLETED